Novartis seeks accelerated FDA approval for pelabresib
Novartis now expects to speak with the FDA about a potential accelerated approval of pelabresib before the end of the year, CEO Vas Narasimhan told investors on a call Tuesday.
on a Tuesday investor call
V
Vas NarasimhanNovartis · CEO
Where it comes from
Geron’s Rytelo stumbles in phase 3 as Novartis gears up for post-JAK inhibitor blood cancer bidWhat the article says
For that indication, Rytelo is dosed at 7.1 mg/kg administered as an intravenous infusion every four weeks. Thrombocytopenia and neutropenia are among some serious side effects tied to the drug that ...
fiercepharma.com